Michael K. Tram

Michael K. Tram

Auto-generated profile, based on publicly available information

Michael K. Tram

Department of Urology, Albany Medical Center, Albany, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2023 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
ALAkshay Lakra
Akshay Lakra
MTMichael K. Tram
Michael K. Tram
TBThomas L. Bernasek
Thomas L. Bernasek
SLSteven T. Lyons
Steven T. Lyons
COCasey M. O’cOnnor
Casey M. O’cOnnor

21 December 2023 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
MTMichael K. Tram
Michael K. Tram
ATAmeer Tabbaa
Ameer Tabbaa
ALAkshay Lakra
Akshay Lakra
AAAfshin A. Anoushiravani
Afshin A. Anoushiravani
TBThomas L. Bernasek
Thomas L. Bernasek
COCasey M. O’cOnnor
Casey M. O’cOnnor

25 January 2022 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
MTMichael K. Tram
Michael K. Tram
COCasey M. O'COnnor
Casey M. O'COnnor
AQAlex S. Qian
Alex S. Qian
JTJennifer T. Tram
Jennifer T. Tram
MTMatthew W. Tetreault
Matthew W. Tetreault

20 December 2023 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
NKNyi-Rein Kyaw
Nyi-Rein Kyaw
MTMichael K. Tram
Michael K. Tram
ALAkshay Lakra
Akshay Lakra
TBThomas L. Bernasek
Thomas L. Bernasek
SLSteven T. Lyons
Steven T. Lyons
COCasey M. O’cOnnor
Casey M. O’cOnnor

1 May 2023 in Urology Practice
Verified
Journal Article
Closed access
MTMichael Tram
Michael Tram
JZJacob Zipkin
Jacob Zipkin
SSShreya Srivastava
Shreya Srivastava
CWCharles Welliver
Charles Welliver
For benign prostatic hyperplasia, clinical trials help assess new medical and surgical treatment options. The U.S. National Library of Medicine maintains ClinicalTrials.gov to provide access to prospective trials on diseases. This study investigates registered benign prostatic hyperplasia trials to determine if there are widespread differences in outcome measures and study criteria. Interventional research with known study status on ClinicalTrials.gov identified by the keywords "benign prostatic hyperplasia" was examined. Inclusion/exclusion criteria, primary outcomes, secondary outcomes, study status, study enrollment, country of origin, and intervention category were studied. Of the 411 studies identified, International Prostate Symptom Score was the most common study outcome and was the primary or secondary study outcome in 65% of trials. Maximum urinary flow was the second most common study outcome (40.1% of studies). No other outcomes were measured as the primary or secondary outcome for more than 30% of studies. The most common inclusion criteria were a minimum International Prostate Symptom Score (48.9%), maximum urinary flow (34.8%), and minimum prostate volume (25.8%). Among studies using a minimum International Prostate Symptom Score, 13 was the most common minimum (35.3%) and a range of 7-21 was noted. The most common maximum urinary flow for inclusion was 15 mL/s (78 trials). Among clinicals trials on benign prostatic hyperplasia registered on ClinicalTrials.gov, a majority of studies utilized International Prostate Symptom Score as a primary or secondary outcome. Unfortunately, there were major differences in the inclusion criteria; these dissimilarities between trials may limit comparability of results across trials.

1 May 2024 in Translational Andrology and Urology
Verified
Journal Article
Open access
PDF file
MTMichael K. Tram
Michael K. Tram
JSJoshua Schammel
Joshua Schammel
RVRachel Vancavage
Rachel Vancavage
CWCharles Welliver
Charles Welliver
BIBrian M. Inouye
Brian M. Inouye
Review Article Emerging strategies for the prevention of bacterial biofilm in prosthetic surgery Michael K. Tram, Joshua Schammel, Rachel Vancavage, Charles Welliver, Brian M. Inouye